Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

Recent News
Aug 14, 2024

- Company reached alignment with the U.S. FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its planned Phase 3b clinical trial for NurOwn® in ALS - SPA in place for Phase 3b...

Aug 7, 2024

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update...

Jul 1, 2024

A conference call and webcast will be held Monday, July 8, at 8:00 a.m. Eastern Time NEW YORK, July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of...

View All

Events
Wednesday, August 14, 2024
8:30am - 9:30am EDT

The replay of the conference call can be accessed by dialing the numbers below and will be available for 14 days.

Replay Numbers
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 51009

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds